RecruitingPhase 2Phase 3NCT05961202

The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

The Efficacy and Mechanism of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy After Myocarditis

Sponsor

Tongji Hospital

Enrollment

200 participants

Start Date

Nov 1, 2021

Study Type

INTERVENTIONAL

Conditions

Myocarditis Inflammatory Cardiomyopathy

Summary

Evaluating the long-term therapeutic effects and safety of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Hydroxychloroquine and a drug called Prednisolone for people with inflammatory cardiomyopathy and myocarditis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.